Humacyte Stock Price, News & Analysis (NASDAQ:HUMA) $2.66 +0.01 (+0.38%) (As of 12/1/2023 ET) Add Compare Share Share Today's Range$2.59▼$2.8450-Day Range$1.99▼$2.9652-Week Range$1.96▼$5.60Volume851,573 shsAverage Volume449,501 shsMarket Capitalization$275.50 millionP/E RatioN/ADividend YieldN/APrice Target$7.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Humacyte MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside191.4% Upside$7.75 Price TargetShort InterestBearish8.13% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.29Based on 2 Articles This WeekInsider TradingSelling Shares$5.56 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($0.94) to ($0.96) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.65 out of 5 starsMedical Sector832nd out of 954 stocksBiological Products, Except Diagnostic Industry145th out of 159 stocks 3.3 Analyst's Opinion Consensus RatingHumacyte has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.75, Humacyte has a forecasted upside of 191.4% from its current price of $2.66.Amount of Analyst CoverageHumacyte has only been the subject of 2 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted8.13% of the float of Humacyte has been sold short.Short Interest Ratio / Days to CoverHumacyte has a short interest ratio ("days to cover") of 10.4, which indicates bearish sentiment.Change versus previous monthShort interest in Humacyte has recently increased by 10.73%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldHumacyte does not currently pay a dividend.Dividend GrowthHumacyte does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for HUMA. Previous Next 2.4 News and Social Media Coverage News SentimentHumacyte has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Humacyte this week, compared to 1 article on an average week.Search InterestOnly 6 people have searched for HUMA on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows3 people have added Humacyte to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Humacyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,560,000.00 in company stock.Percentage Held by Insiders23.10% of the stock of Humacyte is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 27.36% of the stock of Humacyte is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Humacyte are expected to decrease in the coming year, from ($0.94) to ($0.96) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Humacyte is -3.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Humacyte is -3.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHumacyte has a P/B Ratio of 7.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Humacyte Stock (NASDAQ:HUMA)Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.Read More HUMA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HUMA Stock News HeadlinesNovember 24, 2023 | finance.yahoo.comHumacyte to Present at the Piper Sandler 35th Annual Healthcare ConferenceNovember 20, 2023 | seekingalpha.comHumacyte: Upcoming BLA, Pivotal Data, Decent Cash, Excellent OpportunityDecember 1, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.November 18, 2023 | markets.businessinsider.comPromising Clinical Trials and Innovative Technology Bolster Buy Rating for Humacyte StockNovember 17, 2023 | finance.yahoo.comHumacyte Announces Two Presentations at the VEITHsymposium® of Positive Clinical Results of the Human Acellular Vessel™ (HAV™) in the Treatment of Vascular TraumaNovember 14, 2023 | theglobeandmail.comInstrument Name Humacyte Inc Instrument Symbol (HUMA-Q)November 11, 2023 | markets.businessinsider.comPromising Outlook for Humacyte: Buy Rating Highlighted by Strong Pipeline Progress and Financial StabilityNovember 10, 2023 | finance.yahoo.comQ3 2023 Humacyte Inc Earnings CallDecember 1, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.November 10, 2023 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Century Therapeutics (IPSC), Humacyte (HUMA)November 10, 2023 | finanznachrichten.deHumacyte, Inc: Humacyte Third Quarter 2023 Financial Results and Business UpdateNovember 9, 2023 | benzinga.comHumacyte: Q3 Earnings InsightsNovember 9, 2023 | msn.comHumacyte GAAP EPS of -$0.25 in-lineNovember 9, 2023 | finance.yahoo.comHumacyte Third Quarter 2023 Financial Results and Business UpdateNovember 8, 2023 | msn.comHumacyte Q3 2023 Earnings PreviewNovember 8, 2023 | benzinga.comHumacyte's Earnings: A PreviewNovember 2, 2023 | finance.yahoo.comHumacyte to Present Third Quarter Financial Results and Provide Corporate Update on November 9, 2023October 16, 2023 | finance.yahoo.comHumacyte Publishes Preclinical Results Showing Human Acellular Vessel™ (HAV™) Patency as Modified Blalock–Taussig–Thomas Shunt in Juvenile Primate ModelOctober 2, 2023 | finance.yahoo.comSeveral Insiders Invested In Humacyte Flagging Positive NewsSeptember 21, 2023 | msn.comCantor Fitzgerald Reiterates Humacyte (HUMA) Overweight RecommendationSeptember 21, 2023 | finance.yahoo.comHumacyte to Present at the Cantor Global Healthcare ConferenceSeptember 18, 2023 | finance.yahoo.comHumacyte to Host In-Person KOL Event at the New York EDITION on September 20, 2023September 12, 2023 | finance.yahoo.comHumacyte Announces Positive Top Line Results from Phase 2/3 Trial of Human Acellular Vessel™ (HAV™) in Treatment of Patients with Vascular TraumaSeptember 11, 2023 | marketwatch.comStocks to Watch: Oracle, Acelyrin, HumacyteSeptember 11, 2023 | finance.yahoo.comHumacyte to Announce Top Line Data from Phase 2/3 V005 Trial in Vascular Trauma Evaluating its Human Acellular Vessel™ (HAV™) Tuesday, September 12, 2023 at 8:00 AM ETAugust 22, 2023 | msn.comHumacyte: Major Catalysts Ahead, Solid Prospects, Low PricesAugust 21, 2023 | msn.comAlleged Russian crime boss sanctioned by Ukraine owns a major stake in US biotech firmSee More Headlines Receive HUMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Humacyte and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2023Today12/01/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/22/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:HUMA CUSIPN/A CIK1818382 Webwww.constellationalpha.com Phone919-313-9633FaxN/AEmployees164Year FoundedN/APrice Target and Rating Average Stock Price Target$7.75 High Stock Price Target$16.00 Low Stock Price Target$3.00 Potential Upside/Downside+191.4%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.87) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-11,970,000.00 Net MarginsN/A Pretax Margin-286,051.63% Return on Equity-124.36% Return on Assets-52.40% Debt Debt-to-Equity Ratio0.46 Current Ratio6.79 Quick Ratio6.79 Sales & Book Value Annual Sales$1.57 million Price / Sales175.48 Cash FlowN/A Price / Cash FlowN/A Book Value$0.36 per share Price / Book7.39Miscellaneous Outstanding Shares103,570,000Free Float79,649,000Market Cap$275.50 million OptionableOptionable Beta1.22 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Laura E. Niklason M.D. (Age 60)Ph.D., Founder, President, CEO & Director Comp: $717.85kMr. Dale A. Sander (Age 63)CFO, Chief Corporate Development Officer & Treasurer Comp: $667.45kDr. Shamik J. Parikh M.D. (Age 50)Chief Medical Officer Comp: $514.72kDr. Juliana L. Blum Ph.D.Co-Founder & Executive AdvisorDr. Heather Ledbetter Prichard Ph.D. (Age 45)Chief Operating Officer Comp: $576.44kMs. Sabrina OsborneExecutive Vice President of Business Strategy & PeopleMr. William John Scheessele (Age 51)Chief Commercial Officer Mr. Harold AltersonSenior Vice President of QualityDr. Yang Cao M.D. (Age 57)Ph.D., Chief Regulatory Officer More ExecutivesKey CompetitorsAgenusNASDAQ:AGENPoseida TherapeuticsNASDAQ:PSTXTScan TherapeuticsNASDAQ:TCRXFate TherapeuticsNASDAQ:FATEVoyager TherapeuticsNASDAQ:VYGRView All CompetitorsInsiders & InstitutionsWolverine Trading LLCBought 10,200 shares on 11/16/2023Ownership: 0.000%GSA Capital Partners LLPBought 207,333 shares on 11/15/2023Ownership: 0.344%Rokos Capital Management LLPBought 110,097 shares on 11/15/2023Ownership: 0.193%Clough Capital Partners L PBought 79,309 shares on 11/14/2023Ownership: 0.077%California State Teachers Retirement SystemSold 6,858 shares on 11/14/2023Ownership: 0.013%View All Insider TransactionsView All Institutional Transactions HUMA Stock Analysis - Frequently Asked Questions Should I buy or sell Humacyte stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Humacyte in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" HUMA shares. View HUMA analyst ratings or view top-rated stocks. What is Humacyte's stock price target for 2024? 3 brokerages have issued 12-month price objectives for Humacyte's shares. Their HUMA share price targets range from $3.00 to $16.00. On average, they anticipate the company's stock price to reach $7.75 in the next year. This suggests a possible upside of 191.4% from the stock's current price. View analysts price targets for HUMA or view top-rated stocks among Wall Street analysts. How have HUMA shares performed in 2023? Humacyte's stock was trading at $2.11 at the start of the year. Since then, HUMA stock has increased by 26.1% and is now trading at $2.66. View the best growth stocks for 2023 here. Are investors shorting Humacyte? Humacyte saw a increase in short interest in November. As of November 15th, there was short interest totaling 6,090,000 shares, an increase of 10.7% from the October 31st total of 5,500,000 shares. Based on an average daily volume of 583,200 shares, the short-interest ratio is currently 10.4 days. Currently, 8.1% of the shares of the stock are short sold. View Humacyte's Short Interest. When is Humacyte's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, March 22nd 2024. View our HUMA earnings forecast. How were Humacyte's earnings last quarter? Humacyte, Inc. (NASDAQ:HUMA) posted its earnings results on Thursday, November, 9th. The company reported ($0.25) EPS for the quarter, hitting analysts' consensus estimates of ($0.25). What ETFs hold Humacyte's stock? ETFs with the largest weight of Humacyte (NASDAQ:HUMA) stock in their portfolio include Clough Select Equity ETF (CBSE).Clough Long/Short Equity ETF (CBLS). Who are Humacyte's major shareholders? Humacyte's stock is owned by many different retail and institutional investors. Top institutional investors include Northern Trust Corp (0.50%), Charles Schwab Investment Management Inc. (0.44%), GSA Capital Partners LLP (0.34%), LPL Financial LLC (0.33%), Rokos Capital Management LLP (0.19%) and United Asset Strategies Inc. (0.14%). Insiders that own company stock include Brady W Dougan, Dale A Sander, Heather Ledbetter Prichard, Laura E Niklason, Michael T Constantino and William John Scheessele. View institutional ownership trends. How do I buy shares of Humacyte? Shares of HUMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:HUMA) was last updated on 12/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Humacyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.